Our Blog | Halloran

Positioning for the future of clinical research with technology

Biotech companies are being approached with technological advancements that can make drastic improvements in efficiency, speed, and accuracy of clinical trials. But experts see a disconnect between the future of clinical trials and the technology being adopted to support them.

Artificial Intelligence in Medicine: Hope or Hype?

The application of AI in the medical field holds great promise for improving patient health, but will doctors and patients feel comfortable using it? Young startups have begun leveraging this technology to prove better health outcomes, but there's still a lot to do.

Best Practices In FDA Orphan Drug Submissions

Since 1983, pharmaceutical developers have been incentivized by the FDA via an Orphan Drug Designation (ODD) program. The program awards orphan status to drugs that show likelihood of benefitting an afflicted population that might not otherwise be the focus of development efforts.

Amazon in Boston? Biotech leaders see a prime opportunity for collaboration

When Boston unveiled its pitch to land Amazon.com Inc.’s second quarters in October, the city’s 218-page proposal made only passing reference to what is perhaps the state’s most successful industry: biotech.

READY TO TALK?

If you like what you see so far, just wait 'til we start working together. We can't wait to hear about your vision — then help you bring it to life.